April 29, 2025

Can Five Proteins Predict Liver Disease?

"Imagine if we could predict risk of metabolic dysfunction-associated steatotic liver disease (MASLD) years before it starts."

Conexiant

April 24, 2025

Old Drug, New Trick for Joint Pain

Can a common diabetes drug double as a treatment for knee osteoarthritis?

Conexiant

April 21, 2025

Risk-Free Midlife: 10+ Years Longer Living

Prioritizing the prevention and treatment of the modifiable risk factors could substantially extend healthy life expectancy worldwide.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant

September 09, 2024

Bariatric Surgery Outperformed Meds for Hypertension Control

Meta-analysis reveals bariatric surgery patients 7 times more likely to reduce antihypertensive medications compared to conventional treatment.

Conexiant

December 02, 2024

Can Hidden Fat Predict Alzheimer's Risk?

A study presented at RSNA 2024 demonstrated findings at midlife, decades prior to patients exhibiting early symptoms of Alzheimer's disease related dementia.

Conexiant

May 22, 2024

DDW: Adjuvant Therapy May Improve Rectal Adenocarcinoma Survival

Adjuvant therapy may be underutilized in patients with clinical T2N0 rectal adenocarcinoma, according to new findings presented at Digestive Disease Week 2024.

Conexiant

April 01, 2025

AI Scribing and Telephone Management

In his ASCRS 2025 presentation titled "AI Scribing and Telephone Management," Robert T. Chang, MD, shared his insights about how artificial intelligence has impacted his practice and how it can help other practices to be more efficient.

Ophthalmology Management

June 10, 2024

FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative

The Oncology Center of Excellence initiates 'Project 5 in 5,' a crowdsourcing initiative to identify and answer clinically relevant questions using FDA-approved oncology therapies through pragmatic clinical trials over the next 5 years.

The ASCO Post